Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery
Efficacy of Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery: A Double-blind Randomized Controlled Study
Alexandria University
210 participants
May 1, 2025
INTERVENTIONAL
Conditions
Summary
Postoperative nausea and vomiting (PONV) is a common consequence of ambulatory surgery, affecting up to 80% of high-risk patients and 20-30% overall. Despite being widespread, a prior survey found that patients are more averse to PONV than pain and other significant postoperative problems. Furthermore, even mild cases of PONV can have serious repercussions, such as postanesthesia care unit (PACU) workflow disruption, delayed discharges, higher medical costs, and lower patient satisfaction.PONV following intraocular surgery can be unpleasant and may lead to serious complications including suprachoroidal hemorrhage (SCH). SCH is a potentially serious condition that occurs when the posterior ciliary arteries or vortex veins burst, resulting in blood in the suprachoroidal region. The hypothesis is that dexamethasone will lower the incidence of PONV after cataract surgery when compared with metoclopramide.
Eligibility
Inclusion Criteria2
- Age: 40-80 years, both sexes.
- ASA physical status class I to III.
Exclusion Criteria6
- history of motion sickness
- patients with gastrointestinal disorders or gastro-oesophageal reflux
- patients taking medications with known antiemetic activity
- previous postoperative vomiting
- allergy to bupivacaine
- allergy to metoclopramide or dexamethasone
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
patients in group P will receive 0.9% normal saline
patients in group M will receive 10 mg metoclopramide
patients in group D will receive 8 mg dexamethasone
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07086118